The race for antiviral drugs to beat COVID - and the next pandemic.

  title={The race for antiviral drugs to beat COVID - and the next pandemic.},
  author={Elie S Dolgin},
  volume={592 7854},
  • E. Dolgin
  • Published 1 April 2021
  • Medicine
  • Nature
Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity
Doxycycline inhibited the transduction of the pseudotyped virus in Vero E6 and HEK-293 T cells stably expressing human receptor angiotensin-converting enzyme 2 but did not affect the entry and replication of SARS-CoV-2.
Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2
Responding quickly to emerging respiratory viruses, such as SARS-CoV-2 the causative agent of coronavirus disease 2019 (COVID-19) pandemic, is essential to stop uncontrolled spread of these
Nanoagent-based theranostic strategies against human coronaviruses
This review systemically summarized the recent applications of nanoagents in diagnostics and therapeutics for HCoV-induced diseases, as well as their limitations and perspectives against H coV variants, and believes this review will promote the design of innovative theranostic nanoagents for the current and future H CoV-caused pandemics.
Anno 2021: Which antivirals for the coming decade?
The recent progress that has been made in the search for new antivirals against these different threats that the world population will need to confront with increasing frequency in the next decade are summarized.
Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity
IAV DIPs are proposed as an effective antiviral agent for treatment of COVID-19, and potentially also for suppressing the replication of new variants of SARS-CoV-2.
Antivirals for Coexistence with COVID-19: Brief Review for General Physicians
Although the severe acute respiratory syndrome coronavirus 2 will not be completely eradicated, if the use of antiviral drugs is established, the COVID-19 pandemic will end through coexistence with the virus.
Biophysical Measurement Strategies for Antiviral Drug Development: Recent Progress in Virus-Mimetic Platforms Down to the Single Particle Level.
This Account summarizes biophysical measurements that the group has successfully adopted to develop broad-spectrum antiviral drugs based on the lipid envelope antiviral disruption (LEAD) strategy, targeting the structural integrity of the outer viral membrane to abrogate viral infectivity.
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Two non-antiviral therapeutic agents are described, the caspase-1 inhibitor SDZ 224015 and Tarloxotinib that target Mpro and PLpro, respectively that have both undergone safety evaluation in humans and hence are candidates for COVID-19 clinical evaluation.
Broad spectrum antiviral nucleosides—Our best hope for the future
A brief summary of prominent nucleoside analogues that previously exhibited broad-spectrum activity and are now under renewed interest, as well as new analogues, that are currently under investigation against SARS-CoV-2 and other viruses is discussed herein.
Chemoinformatics and Machine Learning Approaches for Identifying Antiviral Compounds.
The study demonstrated scaffold analysis of the molecules as a pragmatic approach to explore the importance of structurally diverse compounds in data driven studies and developed Machine Learning based predictive models that can be used to assess whether a compound has the potency to be antiviral or not.


An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
A ribonucleoside analog inhibits SARS-CoV-2 in human airway epithelial cell cultures and SARS-CoV and MERS-CoV in mice. Catastrophic consequences Broad-spectrum antivirals are desirable, particularly
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Remdesivir for the Treatment of Covid-19 — Final Report
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.
Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide
An amphiphatic peptide is now shown to penetrate the blood–brain barrier, reducing viral loads due to its activity against Zika and other mosquito-borne viruses.
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo and may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.
  • 2004